Summary The extracellular pH (pHe) of solid tumours is often lower than in normal tissues, and this may influence the uptake and/or activity of anti-cancer drugs. The cytotoxicity of mitoxantrone, paclitaxel and topotecan was therefore assessed at low pHe and after manipulation of intracellular pH (pH) in murine EMT6 and in human MGH-U1 cells. The cytotoxic efficacy of all three agents was reduced at PHe 6.5 as compared with PHe 7.4. The ionophore nigericin and inhibitors of membrane-based ion exchange mechanisms that regulate pH, (5-[N-ethyl-N-isopropyl] amiloride, EIPA; 4,4-diisothiocyanstilbene 2,2-disulphonic acid, DIDS) were used to cause intracellular acidification. Combined use of the cytostatic drugs with pH, modifiers reduced their cytotoxicity under both physiological and low-pHe conditions. The uptake into cells of mitoxantrone (a weak base) was inhibited at PHe 6.5 as compared with pHe 7.4, and smaller effects of low PHe to inhibit uptake of topotecan were also observed. DNA analysis of cell cycle distribution revealed that intracellular acidification, as observed during incubation at low pHe and/or using pHi modifiers, resulted in accumulation of cells in G, phase, where they may be more resistant to these drugs. Reduced uptake of weak bases (mitoxantrone) at low PHe and altered cell cycle kinetics upon acidification are the postulated causes of reduced cytotoxicity of the agents investigated.
the pH (pHe) is often lower than in normal tissues (Wike-Hooley et al, 1984; Vaupel et al, 1989) . In contrast, intracellular pH (pHi) as assessed by 3'P magnetic resonance spectroscopy is usually maintained at physiological levels in both tumours and normal tissues, as is expected for the survival of constituent cells, although severely hypoxic tumours may have lower pH, values (Vaupel et al, 1994) . The maintenance of physiological values of pHi in the face of an acidic PHe depends on the buffering capacity of the cell and on membrane-based ion exchangers, the Na+/H+ antiport and the Na+-dependent HCO3-/Cl-exchange mechanism (Madshus et al, 1988; Boyer et al, 1992) . These exchangers may be inhibited respectively by amiloride and its analogues amiloride, EIPA) and by stilbene derivatives (e.g. 4,4-diisothiocyanstilbene 2,2-disulphonic acid, DIDS).
The presence of an H+ gradient across the membrane of tumour cells has implications for chemotherapy. Acidic values of PHe are likely to facilitate the uptake of weak acids, such as melphalan (Skarsgaard et al, 1995) , as more of the compound will be in the uncharged form at low values of PHe (Karuri et al, 1993) . In contrast, extracellular acidity will inhibit the uptake of weak bases such as doxorubicin (Alabaster et al, 1989) . These effects may be modified by agents that dissipate the pH gradient across the membrane (e.g. the K+/H+ exchange ionophore, nigericin) and/or by inhibition of the membrane-based exchange mechanisms that regulate pH, (Parkins et al, 1996) .
Paclitaxel, mitoxantrone and topotecan (9-dimethyl-aminomethyl-20-hydroxy-camptothecin) are anti-cancer drugs that are gaining increasing importance in the therapy of solid tumours. In the present paper we assess the influence of acidic PHe on their uptake and/or activity, and the influence on their cytotoxicity of agents that modify the pH gradient across the cell membrane. Thirty minutes before pHi measurement, 2 ig ml-' BCECF-AM was added to the samples. After dye loading, the coverslips were rinsed in phosphate-buffered saline (PBS) and the ratio of intracellular fluorescence emission at 525 nm after excitation at 495 nm (pHi sensitive) to that at 440 nm (pHi insensitive) was determined. A fluorescence calibration curve for different pHi values was established using the ionophore nigericin and solutions containing 140 mm K+, as described elsewhere (Boyer et al, 1992) .
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Uptake of mitoxantrone and topotecan
The uptake of mitoxantrone into cells, as shown in Figure 2A and B, was approximately twofold higher at PHe 7.4 than at PHe 6.5
(EMT6 cells P < 0.01, MGH-Ul cells P < 0.05). A small increase in cellular accumulation of mitoxantrone at both pHe values was observed when the Na+/H+ antiport and the Na+-dependent HCO3-/Cl-exchanger were blocked with 10 ,UM EIPA and 100 gM DIDS respectively. When cells were incubated in the presence of nigericin, with or without EIPA and DIDS, uptake of mitoxantrone was slightly greater at PHe 7.4, and similar at pHe 6.5, to uptake under control conditions. The uptake of topotecan into EMT6 and MGH-Ul cells is shown in Figure 2C and D. Treatment with EIPA and DIDS in British Journal of Cancer (1997) 75(8), [1167] [1168] [1169] [1170] [1171] [1172] combination did not alter the uptake of topotecan at pHe 7.4 or 6.5.
Nigericin increased significantly the uptake of topotecan at PHe 7.4 but only minimally at pHe 6.5. When all three pHi modifiers were added, drug uptake decreased to control levels at PHe 7.4 and to values lower than under control conditions at PHe 6.5.
Cell survival experiments
Greater cytotoxicity for each drug was observed at PHe 7.4 than at PHe 6.5 in both cell lines investigated (Figures 3 and 4) . The effects of modifiers of pH, on cytotoxicity are shown for EMT6 cells in Figure 5 . Similar results were found for MGH-U1 cells (data not shown).
The drug concentration equivalent to LD90 was chosen for experiments using pHi modifiers, as it should be possible to determine both increases or decreases in cytotoxicity within one experiment. The pHi modifiers alone (EIPA 10 gM, DIDS 100 gM and nigericin 0.3 gM) did not exert significant cytotoxicity. Only the combination of all three agents at PHe 6.5 caused significant cell kill, as has been described previously (Rotin et al, 1987) . The cytotoxicity of mitoxantrone was reduced substantially in the presence of EIPA and DIDS. When incubated with nigericin, the cytotoxicity of mitoxantrone was decreased both at PH. 7.4 and 6.5 by a factor of 2. When all three pH, modifiers were incubated with mitoxantrone, the observed cytotoxic effects were not different to the pH. (Table) .
DISCUSSION
The present study addresses two questions: (a) whether low PHe (6.5), as can be found in acidic regions of many solid tumours, influences the cytotoxicity of mitoxantrone, paclitaxel and topotecan; and (b) the effects of intracellular acidification using EIPA, DIDS and nigericin, on the cytotoxic potency of these drugs. Our results show that the in vitro cytotoxic effects of all three drugs for EMT6
and MGH-Ul cells are reduced at low pHe, and that their effects are not enhanced by agents that induce intracellular acidification.
Our findings support the results of Jahde et al (1990) , who reported a decrease in cytotoxicity of mitoxantrone at low pHe.
Our data on mitoxantrone uptake show that there is a substantial decrease in cellular accumulation at PHe 6.5 when compared with PHe 7.4, which is consistent with the observed decrease in mitoxantrone cytotoxicity at PHe 6.5. We observed a slight increase in cellular accumulation of mitoxantrone when pH. modifiers EIPA and DIDS were added. This effect is in contrast to the results of a study of the effects of EIPA and DIDS on accumulation of doxorubicin (Asaumi et al, 1995 (Huizing et al, 1995) , the total charge of the paclitaxel molecule is unlikely to be a simple function of pHel and it is therefore difficult to predict the effect of pH on drug uptake. Topotecan, a topoisomerase I inhibitor, exists as a lactone species, which is considered to be the bioactive form, and as a carboxylate species, which represents the bioinactive form of the drug (Potmesil, 1994) . Hydrolysis of the lactone form to the carboxylate species is very rapid under physiological conditions (pH approximately 7, 37°C); Owing to its positive charge, the (Musgrove et al, 1987) . This effect was observed more rapidly in EMT6 than in MGH-U1 cells (Table) . It has been shown that HeLa and SQ20B cells are most sensitive to paclitaxel and docetaxel in S-phase and most resistant in G!GI phase (Hennequin et al, 1996) , thus providing a plausible explanation for the approximately threefold decrease in cytotoxicity when paclitaxel was incubated with cells at low pHe with or without pHi modifiers. This effect probably contributes also to resistance to mitoxantrone (Sundman-Engberg et al, 1996) and topotecan, as most cytostatic drugs are more active against cycling cells.
Our results suggest that low values of PHe might contribute to resistance of solid tumours to mitoxantrone, paclitaxel and topotecan. As values of PHe in certain areas of solid tumours are known to be acidic, cells from these regions are more likely to survive and repopulate a tumour after chemotherapy with agents showing decreased cytotoxic potency under acidic conditions. Our results do not suggest that manipulation of the pH gradient across the cell membrane with EIPA, DIDS and/or nigericin will increase the therapeutic effectiveness of these drugs.
ABBREVIATIONS ELPA, amiloride; DIDS, 4,4-diisothiocyanstilbene 2,2-disulphonic acid; a-MEM, alpha-minimum essential medium; BCECF-AM, 2',7'-bis-(2-carboxyethyl)-5-(and 6)-carboxyfluorescein acetomethyl ester; pHe, extracellular pH; pHl, intacellular pH; Hepes, N-2-hydroxyethyl piperazine-N'-2-ethanesulphonic acid;
Bis-Tris, bis(2-hydroxyethyl)imino-tris(hydroxymethyl) methane.
